23andMe PGS Genetic Risk Report for Hereditary Prostate Cancer (HOXB13-Related)
FDA 510(k) clearance K211499 · decided 2022-01-06
Clearance details
- K-number
- K211499
- Device name
- 23andMe PGS Genetic Risk Report for Hereditary Prostate Cancer (HOXB13-Related)
- Applicant
- 23AndMe, Inc.
- Decision
- Substantially Equivalent
- Date received
- 2021-05-14
- Decision date
- 2022-01-06
- Days to decision
- 237 days
- Clearance type
- Traditional
- Product code
- QAZ
- Device class
- 2
- Regulation number
- 866.6090
- Medical specialty
- Medical Genetics
- Advisory committee
- Medical Genetics
- Location
- San Franciso, CA, US
- Third-party review
- No
- Expedited review
- No
+ Add to Predicate Builder ◉ Watch 23AndMe
The Builder collects up to 8 candidate devices side by side with yours, then exports the substantial-equivalence comparison scaffold. How it works
Need this as data, not a web page?
Query all 176,000+ clearances through the Atlas FDA API, or subscribe to weekly change alerts. Self-serve from $29/mo.
Similar devices under this product code
Devices cleared under the same product code - the starting set for predicate research.
| Record | Firm | Date |
|---|---|---|
| 23andMe® Personal Genome Service® (PGS®) Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) (K223597) | 23AndMe, Inc. | 2023-08-31 |
| MUTYH-Associated Polyposis (MAP) (K182784) | 23AndMe, Inc. | 2019-01-18 |
| 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) (DEN170046) | 23AndMe, Inc. | 2018-03-06 |
Recalls involving this device
No recalls on record reference this clearance.